Back

Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with distinct homologous recombination deficiency associated DNA aberration profiles

Diossy, M.; Tisza, V.; Li, H.; Zhou, J.; Sztupinszki, Z.; Young, D.; Nousome, D.; Kuo, C.; Chen, Y.; Ebner, R.; Sesterhenn, I. A.; Moncur, J. T.; Chesnut, G. T.; Petrovics, G.; Klus, G. T.; Spisak, S.; Valcz, G.; Nuzzo, P. V.; Ribli, D.; Schina, A.; Borcsok, J.; Prosz, A.; Krzystanek, M.; Ried, T.; Szuts, D.; Kaochar, S.; Pathania, S.; D'Andrea, A. D.; Csabai, I.; Srivastava, S.; Dobi, A.; Freedman, M. L.; Szallasi, Z.

2021-02-11 oncology
10.1101/2021.02.08.21251199 medRxiv
Show abstract

Chromodomain helicase DNA-binding protein 1 (CHD1) is frequently deleted in a subset of prostate cancers. We show here that subclonal deletion of CHD1 is nearly three times as frequent in prostate tumors of African American men than in men of European ancestry and it associates with rapid disease progression. We further show that CHD1 deletion is associated with only one type of the homologous recombination deficiency associated mutational signatures in prostate cancer. In prostate cancer cell line models CHD1 deletion did not induce HRD as detected by RAD51 foci formation assay, which was consistent with the moderate increase of olaparib sensitivity. CHD1 deficient prostate cancer cells, however, still showed markedly increased sensitivity to talazoparib, which could be effective for the treatment of CHD1 deficient tumors in the context of hormone therapy resistant prostate cancer.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.